All In Biotech

Drug Trial Radar · NCT04845945

MISP 60528 Pneumococcal Vaccination

Response to Guideline-concordant Pneumococcal Vaccination Strategy in Cardiac Transplant Candidates and Recipients

Last checked: Nov 19, 2026Latest source record: Feb 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

4

Actual

Start

Jun 10, 2021

Primary completion

Aug 24, 2024

Study completion Aug 24, 2024

Sponsor

Lead sponsor
Montefiore Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Merck Sharp & Dohme LLC; Sunfire Biotechnologies; Quest Clinical Research
First posted
Apr 15, 2021

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years

Summary

As written by the sponsor on the registry.

This study aims to use two different blood tests (ELISA and OPA) to study response to pneumococcal vaccination administered as per standard guidelines in patients who are undergoing workup for heart transplant (whether or not they have undergone LVAD implantation or have undergone heart transplant.

Conditions

  • Heart Transplant Infection Prevention

Interventions

  • PCV15Biological

    Blood draw after the vaccination

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Vaccine responseTime frame: 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Montefiore Medical Center, Infectious Diseases

    The Bronx, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.